A5090160947- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Colorectal Cancer Treatments and Studies
- Cancer and Skin Lesions
- Chronic Lymphocytic Leukemia Research
- Cancer Diagnosis and Treatment
- Polyomavirus and related diseases
- Immunotherapy and Immune Responses
- Sarcoidosis and Beryllium Toxicity Research
- Cutaneous lymphoproliferative disorders research
- Drug-Induced Adverse Reactions
- Urticaria and Related Conditions
- Brain Metastases and Treatment
- Multiple Myeloma Research and Treatments
- HER2/EGFR in Cancer Research
- Autoimmune Bullous Skin Diseases
- Ferroptosis and cancer prognosis
- Viral-associated cancers and disorders
- Ocular Oncology and Treatments
- Renal cell carcinoma treatment
- Computational Drug Discovery Methods
- Inflammatory Biomarkers in Disease Prognosis
Hôpital Cochin
2015-2024
Université Paris Cité
2010-2024
Assistance Publique – Hôpitaux de Paris
2015-2024
Centre Léon Bérard
2023
Inserm
2018-2021
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2021
Institut des Maladies Génétiques Imagine
2021
Université Paris-Saclay
2021
Cochin University of Science and Technology
2019
John Wiley & Sons (United States)
2018
To report the clinicopathologic features and outcome of myositis in patients treated with immune checkpoint inhibitors (ICIs) (irMyositis).We retrospectively analyzed diagnosed irMyositis tertiary centers Paris, France, Berlin, Germany, from January 2015 to July 2017. The main outcomes were clinical manifestations muscle histology, which included major histocompatibility complex class I (MHC-I), C5b-9, CD3, CD4, CD8, CD20, CD68, programmed cell death protein 1 (PD-1), ligand (PD-L) 1, 2...
Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy ICIs in disease cancer.A retrospective cohort conducted January 2017 2018 via 3 French national networks experts oncology autoimmunity. Adults who were receiving assessed occurrence flare disease, other IRAEs,...
Abstract Background The 18-gene tumor inflammation signature (TIS) is a clinical research assay that enriches for benefit to immune checkpoint blockade. We evaluated its ability predict of immunotherapy in cancer patients treated with PD-1 inhibitors routine care. Methods CERTIM cohort prospective which includes receiving Cochin University hospital. RNA extracted from 58 archival formalin fixed paraffin embedded blocks (including 38 lung cancers, 5 melanomas, 10 renal carcinomas, 4...
Checkpoint inhibitors have significantly improved the prognosis of patients with advanced melanoma. These cancer immunotherapy drugs specific endocrine autoimmune toxicity. We describe a case an adrenal insufficiency secondary to pembrolizumab, anti-programmed cell death-1 monoclonal antibody. Moreover, this polyendocrinopathy resulting from pembrolizumab as occurred after thyroiditis. A 55-year-old female was started on for metastatic choroidal Five months initiation, she suffered...
Abstract While the spectrum of neurological immune checkpoint inhibitor-related adverse events is expanding, patients’ outcomes are not well documented. This study aimed to assess immune-related and identify prognostic factors. All patients experiencing grade ≥2 identified at two clinical networks (French Reference Center for Paraneoplastic Neurological Syndromes, Lyon; OncoNeuroTox, Paris) over five years were included. Modified Rankin scores assessed onset, 6, 12, 18 months, last visit. A...
Immune checkpoint inhibitors (ICI) significantly improve overall survival (OS) in patients with advanced melanoma, but immune-related colitis may occur and warrant anti-tumor necrosis factor α (TNFα) treatment severe forms. A nationwide, multicenter retrospective survey was conducted to assess both, the real-life incidence of grade 3/4 ICI-induced treated anti-TNFα, consequence this therapeutic strategy on disease outcome. All melanoma anti-TNFα agents for ICI-related participating centers...
The objective was to assess the response rate and survival of patients with metastatic mucosal melanoma (MM) uveal (UM) treated anti-CTLA-4 or anti-PD-1 monoclonal antibodies (mAbs). A multicenter retrospective study performed in 25 dermatology departments France. All stage III-C IV MM UM who were mAbs between 2008 2016 included compared after adjustment for main prognostic factors a second cohort chemotherapy. Tumor evaluated according RECIST v. 1.1 criteria at Week 12....
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value not yet demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), (OS), duration of (DOR) safety. The 245 (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group...
<h3>Importance</h3> This case series highlights the risk of uveitis in patients treated with vemurafenib for unresectable or metastatic cutaneous melanoma. <h3>Objective</h3> To assess occurrence and severity as an adverse effect therapy. <h3>Design, Setting, Patients</h3> In this observational small series, data were collected successively from May 1, 2012, through February 31, 2013, clinical signs ocular inflammation at Department Ophthalmology, Cochin-Hôtel-Dieu Hospital. <h3>Main...
Abstract Background Classic Kaposi's sarcoma ( CKS ) occurs predominantly among elderly men and is associated with sarcoma‐associated herpesvirus KSHV ). In low‐endemic countries, infects having sex MSM Objectives To describe a cohort of classic Kaposi in area for , to highlight the features identify prognostic factors. Methods Retrospective single‐centre study cases. We compared heterosexual patients. Then, we divided patients into two subgroups, those requiring systemic treatment others,...
Immune checkpoint inhibitors for melanoma improve adaptive T cell immunity during COVID-19 without exacerbating inflammation.
<b><i>Background:</i></b> Vemurafenib, a BRAF inhibitor, is first-line treatment for inoperable melanoma. Sarcoidosis has never been reported in patients on vemurafenib. <b><i>Objectives:</i></b> We describe 5 cases of sarcoidosis treated with <b><i>Methods:</i></b> Seventy receiving vemurafenib <i>BRAF</i>-mutated stage III or IV melanoma were our centre. <b><i>Results:</i></b> Five...
To describe the marked clinical and biological responses of a targeted treatment with anti-interleukin-6 (IL-6)-receptor antibody Janus kinase (JAK) inhibitors in patient severe, corticoresistant CNS toxicity immune-checkpoint inhibitor (ICI) therapy.A 58-year-old man was admitted for subacute paraparesis, urinary retention, ascending paresthesia. He under ipilimumab nivolumab metastatic melanoma. Spine MRI disclosed multiple T2-hyperintense, contrast-enhancing longitudinally extensive...
Skin disorders are a major concern in the Paediatric Emergency Department (PED). We provide an accurate evaluation of incidence, characteristics and severity skin seen our PED over 1-year period.A total 20,652 children's medical notes were reviewed single centre, retrospective study University Hospital period. The dermatological analysed on basis different criteria including their patient age, sex ratio, diagnosis, seasonal variations hospitalization rates.A 1897 (9.2%, F/M: 1.2; mean age:...
Neutrophilic eccrine hidradenitis (NEH) is a rare neutrophilic dermatosis, first described in patients undergoing chemotherapy for malignant haemopathy. It has polymorphous clinical features and the association of both histological necessary to make diagnosis. We report two cases NEH treated with BRAF inhibitor (BRAFi), either dabrafenib or vemurafenib, stage IV metastatic melanoma. Disseminated erythematous plaques associated fever polyarthralgia occurred early after initiation treatment...